A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

  • Frentzas, Sophia (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date31/10/24 → 30/10/29

Clinical Trial Phase

  • Phase I